You are here

FDA Expands Sabril (Vigabatrin) Indication to Include Children With Partial Seizures

Drug is approved as adjunctive therapy (October 28)

The FDA has approved Sabril (vigabatrin, Lundbeck) as add-on therapy for the treatment of refractory complex partial seizures (CPS) in children 10 years of age and older who have inadequately responded to several other treatments and if the possible benefit outweighs the risk of vision loss.

This approval expands the age range of the previous indication for vigabatrin as adjunctive therapy for adults with refractory CPS. The drug is not indicated as a first-line agent for refractory CPS.

Of the more than two million Americans with epilepsy, approximately 35% have CPS, which originates from a single region of the brain and can cause impaired consciousness. Approximately 30% to 36% of those with CPS continue to have seizures despite trying multiple therapies and are considered to have refractory CPS.

In addition to its indication for refractory CPS, Sabril (vigabatrin) is approved for use in infants and toddlers 1 month to 2 years of age with infantile spasms if the possible benefit outweighs the potential risk of vision loss.

Source: Lundbeck; October 28, 2013.

Recent Headlines

Despite older, sicker patients, mortality rate fell by a third in 10 years
Study finds fewer than half of trials followed the law
WHO to meet tomorrow to decide on international public heath emergency declaration
Study of posted prices finds wild variations and missing data
Potential contamination could lead to supply chain disruptions
Declining lung cancer mortality helped fuel the progress
Kinase inhibitor targets tumors with a PDGFRA exon 18 mutation
Delayed surgery reduces benefits; premature surgery raises risks
Mortality nearly doubled when patients stopped using their drugs